Cerity Partners
CRL icon

Cerity Partners’s Charles River Laboratories CRL Stock Holding History

Cerity Partners’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$871K Sell
3,840
-245
-6% -$43.6K ﹤0.01% 2080
2026
Q1 		$705K Sell
4,085
-2,163
-35% -$401K ﹤0.01% 2075
2025
Q4 		$1.25M Buy
6,248
+1,623
+35% +$294K ﹤0.01% 1601
2025
Q3 		$724K Buy
+4,625
New +$735K ﹤0.01% 1758
2025
Q1 		– Sell
-3,615
Closed -$710K – 2507
2024
Q4 		$710K Sell
3,615
-1,276
-26% -$246K ﹤0.01% 1576
2024
Q3 		$963K Buy
4,891
+1,943
+66% +$404K ﹤0.01% 1409
2024
Q2 		$609K Sell
2,948
-4,151
-58% -$941K ﹤0.01% 1456
2024
Q1 		$1.92M Buy
7,099
+5,629
+383% +$1.34M 0.01% 989
2023
Q4 		$348K Buy
+1,470
New +$289K ﹤0.01% 1443
2023
Q2 		– Sell
-1,198
Closed -$242K – 1706
2023
Q1 		$242K Sell
1,198
-1,239
-51% -$281K ﹤0.01% 1638
2022
Q4 		$531K Buy
2,437
+458
+23% +$100K ﹤0.01% 922
2022
Q3 		$389K Sell
1,979
-9,083
-82% -$1.96M ﹤0.01% 800
2022
Q2 		$2.37M Sell
11,062
-11,646
-51% -$2.85M 0.03% 374
2022
Q1 		$6.45M Buy
+22,708
New +$7M 0.1% 167

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Cerity Partners's CRL Position: Q2 2026 in Review

Cerity Partners reduced its Charles River Laboratories (CRL) stake by 6% in Q2 2026, selling an estimated $43.6K and leaving 3,840 shares worth $871K. The position accounts for ﹤0.01% of the portfolio, ranked #2080.

Cerity Partners first reported a position in CRL in Q1 2022 and has held it in 14 quarters since. The position peaked at $6.45M in Q1 2022. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Cerity Partners held 3,840 shares of Charles River Laboratories worth $871K as of Q2 2026.
  • Cerity Partners sold 245 Charles River Laboratories shares in Q2 2026, an estimated $43.6K.
  • Charles River Laboratories made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2080 holding.
  • Cerity Partners first reported a position in Charles River Laboratories in Q1 2022 and has held it in 14 quarters since.
  • Cerity Partners's Charles River Laboratories position peaked at $6.45M in Q1 2022.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.